Although we cannot provide further experimental data for masitinib regarding direct brain effects related to neuronal survival, affecting BBB or inflammation in stroke, we have putative evidence from scientific literature that tyrosine kinase inhibitors (including masitinib) poorly cross BBB, and even if they can cross in a small amount they are quickly eliminated from brain tissue by P-glycoprotein (ABCB1 and ABCG2) (Lagas et al. 2009). The gene discussed is ABCG2; the disease is Stroke.